GlassScriptPhysician profile
Samantha B Shaffer
NPI 1255347829
$536.10
in general payments reported to CMS, 2019-2025
11 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.77 · 2022: $77.28 · 2023: $138 · 2024: $83.31 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $124.25 | 2023-2025 | |
| Tactile Systems Technology INC | $108.11 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Supernus Pharmaceuticals, INC. | $71.07 | 2025 | Qelbree |
| Sanofi Pasteur INC. | $62.11 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $44.89 | 2025 | Neffy |
| Corium, LLC | $36.06 | 2023 | Azstarys |
| Seqirus USA INC | $23.00 | 2025 | Flucelvax |
| Astrazeneca Pharmaceuticals LP | $18.98 | 2023 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $18.91 | 2025 | Ycanth |
| Merck Sharp & Dohme LLC | $14.94 | 2023 | Proquad, Vaxneuvance, Vaxelis |
| Novo Nordisk INC | $13.78 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.